2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

5818 Depth versus path to minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM): A real-world multicenter analysis from the ASH research collaborative data hub

Cindy Varga, MD,BSc, Susan Geyer, PhD2, Levi Pederson, MS3, Emily Semmel, MS4, Travis Dockter, MS5, Tony Newberne, BS6, Terry Glassman, BSN7, Peyton Schumacher8, Shaji Kumar, MD9, Shambavi Richard, MD10, Jeffrey A. Zonder, MD11, Ajay K Nooka, MD, MPH12, Joselle M Cook, M.D.13, Shandra James, DNP14, Saad Z. Usmani, MD15, Aaron S Rosenberg, MD16, Samuel Rubinstein, MD MSCI17, Kenneth Anderson, MD18, William Wood, MD, MPH19, Venkatesh Charya, MS20, Anita D'Souza, MD21, Jodi Lipof, MD22, Poy Theprungsirikul, MD23, Hamza Hashmi, M.D.24, Allison Jacob, MS25, Jiefu Wang, PhD26, Jim Dukeman27, Manisha Bhutani, MD28
1 Atrium Health/Levine Cancer Institute, Charlotte, North Carolina, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 ASH RC Hub, Washington, District of Columbia, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 ASH RC Hub, Washington, District of Columbia, United States
7 ASH RC Hub, Washington, District of Columbia, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Icahn School of Medicine at Mount Sinai, New York, United States
11 Karmanos Cancer Institute, Detroit, United States
12 Winship Cancer Institute of Emory University, Atlanta, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 ASH RC Hub, Washington, District of Columbia, United States
15 Memorial Sloan-Kettering Center, New York, New York, United States
16 UC Davis Comprehensive Cancer Center, Sacramento, California, United States
17 University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States
18 Dana-Farber Cancer Institute, Boston, United States
19 University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States
20 University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States
21 Medical College of Wisconsin, Wisconsin, United States
22 University of California, San Francisco, United States
23 Dana-Farber Cancer Institute, Boston, United States
24 Memorial Sloan-Kettering Center, New York, New York, United States
25 Adaptive Biotechnologies, Seattle, United States
26 UC Davis Comprehensive Cancer Center, Sacramento, California, United States
27 Washington University School of Medicine, St. Louis, United States
28 Atrium Health/Levine Cancer Institute, Charlotte, North Carolina, United States

Background: Minimal residual disease (MRD) negativity has emerged as a powerful prognostic marker in multiple myeloma (MM) with sustained MRD negativity consistently associated with superior outcomes. As frontline induction regimens increasingly produce deep responses, the incremental benefit of autologous stem cell transplantation (ASCT) - and specifically its effect on the durability of MRD negativity - remains unresolved. We evaluated baseline characteristics associated with MRD negativity and compared duration of MRD negativity between patients (pts) who did and did not receive ASCT as part of frontline therapy. Methods: We performed a multicenter, retrospective, observational cohort study of pts with newly diagnosed MM (NDMM) treated with triplet or quadruplet induction regimens at 12 U.S academic centers between 2009 and 2024 utilizing data collected through the ASH Research Collaborative Data Hub. Eligible pts had at least one bone marrow MRD assessment by next generation flow cytometry. The primary MRD negativity threshold was 10-5. Duration of MRD negativity was defined as time from MRD negativity to loss of MRD negativity, disease progression (PD) or death, and was estimated using Kaplan-Meier methods. Influence of ASCT and other factors on duration of MRD negativity was assessed using Cox regression models and log rank tests stratified by center. Results: Of the 515 evaluable pts, 64.5% were male; 83% were White and 13.3% were Black or African American. Overall, 350 pts achieved MRD negativity (68.0%) prior to 1st PD. High-risk cytogenetics were equally distributed across pts (MRD+ 23.3% vs. MRD- 27.9%), as was ISS stage 3 disease (MRD- 24.4% vs. MRD+ 30.7%). RVD was the most common induction regimen (57.1% overall); 89.1% of pts received a triplet and 10.9% received a quadruplet regimen. Of the 235 pts who received ASCT in frontline therapy, 113 (48.1%) had ASCT prior to their first MRD testing while the remaining 122 (51.9%) had MRD testing performed before transplant. More pts who received an ASCT achieved MRD negativity at any time point prior to PD compared to pts who did not (75.3% versus 61.8%, p = 0.001). Median time from start of first line therapy to 1st MRD assessment was similar between MRD+ and MRD- pts (165 vs. 161 days). Median time from 1st line therapy to MRD- status was 245.5 days (IQR 163 to 662); > 2/3 of MRD- pts achieved this status within 12 months (mos). Median duration of MRD negativity (10-5) for the overall cohort was 44.6 mos with 37.8% remaining MRD- at five years. In a landmark analysis from first MRD-assessment (n = 231), pts who received ASCT prior to attaining MRD negativity at 10-5 had a shorter duration of MRD negativity (median 24.3 mos, 95% CI 18.9 to 62.5) compared to those without prior ASCT (median 47.4 mos, 95% CI 40.5 to 60.4; p = 0.0032, HR 0.41, 95% CI 0.22 to 0.75, favoring no prior ASCT). At 60 mos, 40.8% of pts without prior ASCT remained MRD- versus 20.5% of those with prior ASCT. Among 219 patients without ASCT prior to MRD negativity, 31 received ASCT as consolidation after documented MRD negativity. Time-dependent covariate Cox regression analysis showed that getting an ASCT while MRD- was not significantly associated with duration of MRD negativity (HR 1.44, 95% CI 0.69 to 3.00; p = 0.33). Conclusion: In this real-world cohort, ASCT was not associated with improved durability of MRD negativity. Because pre-ASCT MRD testing was performed in only 52% of transplanted patients, we used a time dependent covariate Cox model, which showed no significant association between ASCT and MRD duration; a landmark analysis of MRD- duration from the time of first MRD- status similarly favored no prior ASCT (60-month MRD negativity of 40.8% vs. 20.5%). Attaining MRD negativity with induction alone may reflect favorable disease biology, suggesting that MRD negativity itself - not the path to it- drives durability, and supporting prospective evaluation of MRD-adapted transplant deferral.

Cindy Varga, MD,BSc: Janssen - Honoraria; sanofi - Honoraria; mmrc - Research Funding; Janssen - Research Funding; K36 - Research Funding; kite - Research Funding